Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dural sealant enters European trial:

This article was originally published in Clinica

Executive Summary

Confluent Surgical has begun a single-site, European clinical trial of its sprayable synthetic sealant for reducing the rate of cerebrospinal fluid leakage in patients undergoing cranial and spinal surgical procedures. The sealant is indicated for use as an adjunct to standard methods of closure of the dura mater. The product is sprayed onto the tissue at the end of a surgical procedure. It forms a flexible, watertight seal, remains adhered to the tissue during the critical healing period and is then safely absorbed by the body, says the Waltham, Massachusetts firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel